# EDGAR Filing Document

**Accession Number:** 0001304161
**File Stem:** 0001654954-26-002338
**Filing Date:** 2026-3
**Character Count:** 8728
**Document Hash:** 3495348f840017a18b5cbe0935ba4d86
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-26-002338.hdr.sgml**: 20260317

**ACCESSION NUMBER**: 0001654954-26-002338

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260317

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260317

**DATE AS OF CHANGE**: 20260317

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pharma-Bio Serv, Inc.
- **CENTRAL INDEX KEY:** 0001304161
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 200653570
- **FISCAL YEAR END:** 1031

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-50956
- **FILM NUMBER:** 26763515

**BUSINESS ADDRESS:**
- **STREET 1:** INDUSTRIAL ZONE STREET 1
- **STREET 2:** LOT 14
- **CITY:** DORADO
- **STATE:** PR
- **ZIP:** 00646
- **BUSINESS PHONE:** 787-278-2709

**MAIL ADDRESS:**
- **STREET 1:** INDUSTRIAL ZONE STREET 1
- **STREET 2:** LOT 14
- **CITY:** DORADO
- **STATE:** PR
- **ZIP:** 00646

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LAWRENCE CONSULTING GROUP INC
- **DATE OF NAME CHANGE:** 20040923

?xml version='1.0' encoding='ASCII'? pbsv_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) **<u>March 17, 2026</u>**

---

| |
|:---|
| **Pharma-Bio Serv, Inc.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Delaware** | **0-50956** | **20-0653570** |
| (State or other jurisdiction of incorporation) | (Commission<br>File Number) | (IRS Employer <br>Identification No.) |

---

---

| | |
|:---|:---|
| **PO Box 1049**<br>**Dorado, Puerto Rico** | **00646** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code <u>**(787) 278-2709**</u> 

___________________________________________________________

(Former name or former address, if changed since last report)<br>

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02. Results of Operations and Financial Condition.**

On March 17, 2026, Pharma-Bio Serv, Inc. (the "Company") issued a press release announcing its results of operations for the quarter ended January 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](pbsv_ex991.htm) | [Press Release, dated March 17, 2026.](pbsv_ex991.htm) |
| 104 | Cover page Interactive Data File (embedded within the Inline XBRL document). |

---

2<br>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | PHARMA-BIO SERV, INC. | PHARMA-BIO SERV, INC. |
| Date: March 17, 2026  | By:  | /s/ Pedro J. Lasanta |
|  |  | Pedro J. Lasanta  |
|  |  | Chief Financial Officer, Vice President Finance and Administration and Secretary |

---

3<br>

## Exhibit 99.1

**EXHIBIT 99.1**

**Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2026**

**DORADO, PUERTO RICO /<u>ACCESS</u> <u>Newswire</u>/ March 17, 2026 /**Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2026 were approximately $2.3 million, a decrease of approximately $0.2 million when compared to the same period last year. Net income for the quarter ended January 31, 2026 was $32,860, an improvement of $24,324 when compared to the same quarter last year.

"We entered this fiscal year focused on executing the strategic priorities established over the past several quarters—sharpening our service portfolio, reinforcing operational alignment, and concentrating on the markets where our capabilities create the most value. We are encouraged by the progress made in improving operational efficiency, which allowed us to deliver a modest profit compared to a slight loss in the same period last year. As we look ahead, we will continue strengthening client relationships, maintaining disciplined cost management, and aligning our organization with the areas of greatest opportunity. We remain confident that these efforts position us well to build momentum and deliver long term value to our shareholders," said Mr. Sanchez, Chief Executive Officer.

**About Pharma-Bio Serv, Inc.**

Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.

**Forward-Looking Statements**

This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2025, and in its other filings with the Securities and Exchange Commission, which filings are available at <u>www.sec.gov</u>. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

**Company Contact:**

Pedro J. Lasanta

Chief Financial Officer

787 278 2709

**SOURCE:** Pharma-Bio Serv Inc.